NCT02802514 - A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

August 10, 2017

Study Completion Date

September 7, 2017

Conditions

Diabetes Mellitus

Interventions

DRUG

Albiglutide 50mg

It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.

DRUG

Albiglutide matching placebo

It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm

DRUG

Exenatide 10microgram

It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm

DRUG

Exenatide placebo (saline)

It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm

Trial Locations (1)

02114

GSK Investigational Site, Boston